This study evaluates the safety and clinical activity of carbognilumab (DB16680), a PD-1 and CTLA-4 bispecific antibody, in combination with standard chemotherapy in advanced or postoperative recurrent NSCLC with LKB1 mutations. Here, CTLA4 is linked to non-small cell lung carcinoma.